Intellipharmaceutics, Mylan, Par Pharmaceutical sales and marketing update

Intellipharmaceutics said FDA approved 15 and 30 mg dexmethylphenidate extended-release capsules - a generic version of ADHD drug Focalin XR dexmethylphenidate - and U.S. commercialization partner Par will launch the two strengths "immediately." The companies are not disclosing pricing for the product. Intellipharmaceutics said it will have 180 days of generic market exclusivity for the 15 mg strength of the product. The company also said FDA tentatively approved 5, 10, 20 and 40 mg strengths of the product, which Par will launch upon the expiry of the exclusivity periods held by other companies.

Separately, Mylan said its Mylan Pharmaceuticals Inc. subsidiary launched 30 mg dexmethylphenidate extended-release capsules. The company said it has 180 days of generic market exclusivity for the 30 mg strength. Mylan declined to disclose pricing for the product. ...